ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.
Press releases
Keeping you updated
ILC completes investment round and appoints Dr Owain Millington as Vice President and Head of Preclinical Development
Scottish biotech ILC Therapeutics has completed its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including SARS-CoV-2.
ILC signs R&D partnership with Dechra
Scottish biotech ILC Therapeutics has signed a R&D partnership with international veterinary group Dechra Pharmaceuticals PLC which will see both entities develop ILC’s Caniferon product to treat atopic dermatitis in dogs. Atopic dermatitis is the most common form of eczema affecting
Scottish biotech company announces dramatic breakthrough in battle against COVID-19
• Drug also has potential to treat SARS, HIV, hepatitis and respiratory infection (RSV)• Earlier research shows drug is 15-20 times more potent than other interferons• Far fewer side effects than current treatments ILC Therapeutics has completed in vivo tests
ILC Therapeutics strengthens team to accelerate development of COVID-19 drug
Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug. Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including COVID-19.
COVID: Antiviral drugs that boost humans’ ‘interferon’ immune response can help tackle current and future pandemics – Professor William Stimson
As we live through the most rapidly evolving viral environment the world has seen, there is a critical need for effective and safe antiviral medicines to meet the challenges of today and the inevitable threats of tomorrow. Worldwide, we are
ILC Therapeutics announces successful completion of £3.5m funding round
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs…
ILC Therapeutics announces board changes and funding round to accelerate COVID-19 drug
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs…
Inventor of synthetic Interferon discusses potential against COVID-19
An interview with Founder & Chief Scientific Officer William Stimson in Drug Discovery World.
UK COVID-19 drug developer welcomes NHS treatment priority
ILC Therapeutics has welcomed NHS plans to make Covid-19 treatments available to patients as soon as possible.
ILC Therapeutics announces significant investment from Medical Incubator Japan
ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ).
ILC Therapeutics announces 'significant' COVID-19 drug breakthrough
ILC Therapeutics has confirmed that its unique synthetic Interferon called Alfacyte™ is 15 to 20 times more effective at preventing the spread of SARS-CoV-2 Independent research at the University of St Andrews demonstrated the superior effectiveness of Alfacyte™ in vitro
ILC Therapeutics announces partnership with University of St Andrews to combat COVID-19
ILC Therapeutics has struck a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.